[Role of chloramphenicol in current clinical practice].

Q3 Medicine Klinicka mikrobiologie a infekcni lekarstvi Pub Date : 2022-12-01
Olga Džupová, Jiří Beneš
{"title":"[Role of chloramphenicol in current clinical practice].","authors":"Olga Džupová,&nbsp;Jiří Beneš","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chloramphenicol is an antibiotic with a broad spectrum of action and excellent tissue penetration. It had been widely used in clinical practice until the 1970s, but due to its potential myelotoxicity, it was gradually replaced by newly introduced antibiotics in the following years. The aim of the study was to find out to what extent and with what experience it is currently used in the Czech Republic.</p><p><strong>Methods: </strong>A questionnaire survey was conducted in July and August 2022. The heads of all inpatient infectious diseases departments, hospital infectious diseases specialists and consulting microbiologists from antibiotic centers in large teaching hospitals without an infectious diseases department were asked to fill out the questionnaire.</p><p><strong>Results: </strong>Thirty-five out of 39 hospitals contacted took part in the study, a response rate of 90 %. Chloramphenicol is used in 37 % of participating hospitals, with a frequency of up to 10 patients treated per year. The most common indications are brain abscesses, purulent meningitis, intra-abdominal, pelvic and lung abscesses, and polymicrobial infections with anaerobes. Chloramphenicol is almost always administered as an alternative antibiotic because of polyvalent allergy, bacterial resistance, and failure of previous treatment. Sixty-six percent of respondents described the effect as reliable or partially reliable, 34 % did not rate the effect. Fifty-two percent of respondents considered a dose of 8-9 g to be the maximum dose for an adult patient. In practice, 60 % of respondents did not encounter or could not assess the myelotoxic effects of chloramphenicol, 37 % observed reversible bone marrow suppression at least once, and only one respondent encountered aplastic anemia once.</p><p><strong>Conclusion: </strong>Unfortunately, chloramphenicol is currently used in less than half of hospitals in the Czech Republic. Because of its unique properties, it still has a place in today's anti-infective treatment. When properly indicated and after weighing the benefits and risks, it can be a suitable and sometimes life-saving alternative.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"28 4","pages":"101-105"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka mikrobiologie a infekcni lekarstvi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chloramphenicol is an antibiotic with a broad spectrum of action and excellent tissue penetration. It had been widely used in clinical practice until the 1970s, but due to its potential myelotoxicity, it was gradually replaced by newly introduced antibiotics in the following years. The aim of the study was to find out to what extent and with what experience it is currently used in the Czech Republic.

Methods: A questionnaire survey was conducted in July and August 2022. The heads of all inpatient infectious diseases departments, hospital infectious diseases specialists and consulting microbiologists from antibiotic centers in large teaching hospitals without an infectious diseases department were asked to fill out the questionnaire.

Results: Thirty-five out of 39 hospitals contacted took part in the study, a response rate of 90 %. Chloramphenicol is used in 37 % of participating hospitals, with a frequency of up to 10 patients treated per year. The most common indications are brain abscesses, purulent meningitis, intra-abdominal, pelvic and lung abscesses, and polymicrobial infections with anaerobes. Chloramphenicol is almost always administered as an alternative antibiotic because of polyvalent allergy, bacterial resistance, and failure of previous treatment. Sixty-six percent of respondents described the effect as reliable or partially reliable, 34 % did not rate the effect. Fifty-two percent of respondents considered a dose of 8-9 g to be the maximum dose for an adult patient. In practice, 60 % of respondents did not encounter or could not assess the myelotoxic effects of chloramphenicol, 37 % observed reversible bone marrow suppression at least once, and only one respondent encountered aplastic anemia once.

Conclusion: Unfortunately, chloramphenicol is currently used in less than half of hospitals in the Czech Republic. Because of its unique properties, it still has a place in today's anti-infective treatment. When properly indicated and after weighing the benefits and risks, it can be a suitable and sometimes life-saving alternative.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[氯霉素在当前临床中的作用]。
氯霉素是一种具有广谱作用和良好的组织穿透性的抗生素。直到20世纪70年代,它在临床实践中被广泛使用,但由于其潜在的髓毒性,在接下来的几年里,它逐渐被新引入的抗生素所取代。这项研究的目的是找出目前在捷克共和国使用的程度和经验。方法:于2022年7 - 8月进行问卷调查。调查对象为无传染病科的大型教学医院的所有住院传染病科主任、医院传染病专家和抗生素中心的咨询微生物学家。结果:在联系的39家医院中,有35家参与了研究,回复率为90%。37%的参与医院使用氯霉素,每年最多治疗10名患者。最常见的适应症是脑脓肿,化脓性脑膜炎,腹腔,盆腔和肺脓肿,以及厌氧菌的多微生物感染。由于多价过敏、细菌耐药和既往治疗失败,氯霉素几乎总是作为替代抗生素使用。66%的受访者认为效果可靠或部分可靠,34%的受访者认为效果不可靠。52%的答复者认为8- 9g的剂量是成年患者的最大剂量。实际上,60%的受访者没有遇到或无法评估氯霉素的骨髓毒性作用,37%观察到可逆的骨髓抑制至少一次,只有一名受访者遇到再生障碍性贫血一次。结论:不幸的是,目前在捷克共和国不到一半的医院使用氯霉素。由于其独特的性质,它在今天的抗感染治疗中仍然占有一席之地。在适当指出并权衡利弊后,它可能是一种合适的,有时甚至可以挽救生命的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Klinicka mikrobiologie a infekcni lekarstvi
Klinicka mikrobiologie a infekcni lekarstvi Medicine-Infectious Diseases
CiteScore
0.40
自引率
0.00%
发文量
0
期刊最新文献
[Resistance of bacterial pathogens isolated from the lower respiratory tract and their clonality in intensive care patients in a post-COVID-19 period]. [A case of botulism in the Czech Republic and current possibilities for detecting the neurotoxin produced by Clostridium botulinum]. [Microbiological methods for identification of the etiological agents of bloodstream infections with focus on the T2Bacteria Panel]. [Pseudomonas aeruginosa virulence factors as a therapeutic target in multidrug-resistant strains]. [Respiratory manifestations of post-COVID syndrome].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1